Plexxikon Inc.

Opna Bio Sa

Opna Immuno-oncology Sa

Chao Zhang

Prabha N Ibrahim

Jiazhong Zhang

Dean R Artis

Wayne Spevak

Guoxian Wu

Songyuan Shi

Hanna Cho

Jack Lin

Marika Nespi

Ryan Bremer

Ying Zhang

Rebecca Zuckerman

Clarence R Hurt

Todd Ewing

Klaus-Peter Hirth

Shumeye Mamo

Gideon Bollag

Shenghua Shi

Heike I Krupka

Hongyao Zhu

Gaston G Habets

Yong-Liang Zhu

Weiru Wang

James Tsai

Michael V Milburn

Zuojun Guo

James Arnold

Jianming Tsai

Brian L West

John Buell

Samuel J Gillette

Sam Gillette

Byunghun Lee

Cuong Q Ly

Bruce England

Abhinav Kumar

Elizabeth A Burton

Jack Walleshauser

Mark Vander Wal

Phuongly Pham

Hiroaki Inagaki

Jeffrey Yung Wu

Yoshihisa Suzuki

Yong Zhou

Yoshisa Suzuki

Yong Zhu

Yongil Jin

Richard Dean Artis

Helke Krupka

Compounds and methods for CD73 modulation and indications therefor

Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Compounds and methods for EP300 or CBP modulation and indications therefor

Disclosed are compounds having a compound of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, compositions thereof, and uses thereof.

Compounds and methods for kinase modulation

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds active on protein kinases and methods for regulating protein kinase pathways are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds for kinase modulation, and indications therefor

The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.

Kinase modulation, and indications therefor

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described, wherein the compounds have formula Ia:  In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, global ischemia, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type I diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastoma, neurofibromatosis, osteolytic bone metastases, brain metasteses, gastrointestinal stromal tumors, and giant cell tumors.

Compounds of formula (I): and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds of formula (I) or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

Compounds, compositions and methods useful for treatment of Flt3-mediated diseases or conditions are provided herewith. Also provided herewith are methods for modulating the receptor protein tyrosine like kinase 3(Flt3).

Kinase modulation and indications therefor

Growing community of inventors

Moraga, CA, United States of America

Chao Zhang